NKT cell recognition

Lead researcher

Professor James McCluskey, Dr Jamie Rossjohn

University of Melbourne

Years funded

The immune system can sometimes identify cancerous cells and kill them through "immune surveillance". In some cases, even established tumours can be eradicated by immune cells that infiltrate the tumour and kill off the malignant cells. However the immune system usually requires signals such as inflammation that engenders activation of cells in order to achieve this outcome.

A key goal in the field of tumour immunology is to understand the mechanisms by which tumour cells are eliminated by the activated immune system. In particular it is important to know the different cell types responsible for tumour elimination, how these cells are activated and how they discriminate tumour cells from normal tissues. In this research project we will focus on one aspect of this process mediated a novel set of T lymphocytes known as NKT cells.

These NKT cells are believed to be important in facilitating immunity to a variety of tumours, through the recruitment of other cell types and perhaps via direct tumour recognition. NKT cells essentially have a single type of receptor for recognizing tumour molecules. This receptor is the same in all individuals and recognizes a molecule called CD1d that binds glycolipids and other small molecules manufactured by living cells. It is unclear how this receptor binds the CD1d molecule and what allows it to differentiate between normal glycolipids and those that induce anti-tumour immunity.

It is also not known whether the tumours themselves make the glycolipids that are recognized by NKT cells. We will determine the 3-dimensional structure of the human NKT receptor by itself and when it is bound to a CD1d-glycolipid complex.

By engineering the NKT receptor we hope to be able to use this as a reagent to scan for cells expressing the tumour glycolipid. A knowledge of the structure of NKT cell receptors bound and unbound to their target molecule (CD1d/glycolipid) will be of fundamental importance in the field of tumour immunity.

Award / Duration

Research Grant: 2006-2008


$70,000 per annum